Non-invasive imaging for studying anti-angiogenic therapy effects

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 375-390

  Ehling, J ^a,b   Lammers, T ^a,c   Kiessling, F ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Angiogenesis; Cancer therapy; Functional imaging; Molecular imaging; Vessel normalisation

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE MEGLUMINE; IODINE; IOHEXOL; IRINOTECAN; MONOCLONAL ANTIBODY DC101; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1, 2, 3 TRIAZOL 1 YL) ETHOXY] 4 QUINAZOLINAMINE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PADOPORFIN; SHU 508; SUNITINIB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; ARTICLE; BLOOD VOLUME; ECHOGRAPHY; HUMAN; IMAGING; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PHOTOACOUSTICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARY PERMEABILITY; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY; X-RAY MICROTOMOGRAPHY;

EID: 84874777716     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0721     Document Type: Article

References (100)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
5. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
6. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-111.
7. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713-725.
8. Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172-187.
9. Lederle W, Palmowski M, Kiessling F. Imaging in the age of molecular medicine: monitoring of anti-angiogenic treatments. Curr Pharm Biotechnol 2012; 13: 595-608.
10. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med 2003; 47: 171-187.
11. d'Assignies G, Couvelard A, Bahrami S et al. Pancreatic endocrine tumours: tumour blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009; 250: 407-416.
12. Ohno Y, Koyama H, Matsumoto K et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology 2011; 258: 599-609.
13. Schambach SJ, Bag S, Steil et al. Ultrafast high-resolution in vivo volume-CTA of mice cerebral vessels. Stroke 2009; 40: 1444-1450.
14. Figueiredo G, Brockmann C, Boll H et al. Comparison of digital subtraction angiography, micro-computed tomography angiography and magnetic resonance angiography in the assessment of the cerebrovascular system in live mice. Clin Neuroradiol 2012; 22: 21-28.
15. Bartling SH, Stiller W, Semmler W et al. Small animal computed tomography imaging. Curr Med Imaging Rev 2007; 3: 45-49.
16. Vera DR, Mattrey RF. A molecular CT blood pool contrast agent. Acad Radiol 2002; 9: 784-792.
17. Kao CY, Hoffman EA, Beck KC et al. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol 2003; 10: 475-483.
18. De Vries A, Custers E, Lub J et al. Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents. Biomaterials 2010; 31: 6537-6544.
19. Kiessling F, Greschus S, Lichy M et al. Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumour angiogenesis. Nat Med 2004; 10: 1133-1138.
20. Eisa F, Brauweiler R, Hupfer M et al. Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response. Eur Radiol 2012; 22: 900-907.
21. Tai JH, Tessier J, Ryan AJ et al. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumour xenograft model in the nude rat. Neoplasia 2010; 12: 697-707.
22. Bäuerle T, Bartling S, Berger M et al. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol 2010; 73: 280-287.
23. Granton PV, Pollmann SI, Ford NL et al. Implementation of dual-and tripleenergy cone-beam micro-CT for postreconstruction material decomposition. Med Phys 2008; 35: 5030-5042.
24. Gremse F, Grouls C, Palmowski M et al. Virtual elastic sphere processing enables reproducible quantification of vessel stenosis at CT and MR angiography. Radiology 2011; 260: 709-717.
25. Savai R, Langheinrich AC, Schermuly RT et al. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 2009; 11: 46-56.
26. Papenfuss HD, Gross JF, Intaglietta M et al. A transparent access chamber for the rat dorsal skin fold. Microvasc Res 1979; 18: 311-318.
27. Leunig M, Yuan F, Menger MD et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992; 52: 6553-6560.
28. Lichtenbeld HC, Barendsz-Janson AF, van Essen H et al. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int J Cancer 1998; 77: 455-459.
29. Vakoc BJ, Lanning RM, Tyrrell JA et al. Three-dimensional microscopy of the tumour microenvironment in vivo using optical frequency domain imaging. Nat Med 2009; 15: 1219-1223.
30. Hansen-Algenstaedt N, Joscheck C, Schaefer C et al. Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. Eur J Cancer 2005; 41: 1073-1085.
31. Kiessling F, Jugold M, Woenne EC et al. Non-invasive assessment of vessel morphology and function in tumours by magnetic resonance imaging. Eur Radiol 2007; 17: 2136-2148.
32. Glunde K, Jiang L, Moestue SA et al. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed 2011; 24: 673-690.
33. Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 2012; 35: 257-279.
34. Wheaton AJ, Miyazaki M. Non-contrast enhanced MR angiography: physical principles. J Magn Reson Imaging 2012; 36: 286-304.
35. Doblas S, He T, Saunders D et al. Glioma morphology and tumour-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography. J Magn Reson Imaging 2010; 32: 267-275.
36. Kiessling F, Farhan N, Lichy MP et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004; 6: 213-223.
37. Luo Y, Jiang F, Cole TB et al. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumour vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol 2012; 69: 911-921.
38. Dafni H, Kim SJ, Bankson JA et al. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008; 60: 822-833.
39. Lee L, Sharma S, Morgan B et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2006; 57: 761-771.
40. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
41. Liu G, Rugo HS, Wilding G et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumours: results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
42. Troprès I, Lamalle L, Péoc'h M et al. In vivo assessment of tumoural angiogenesis. Magn Reson Med 2004; 51: 533-541.
43. Zwick S, Strecker R, Kiselev V et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009; 29: 1125-1133.
44. Walker-Samuel S, Boult JK, McPhail LD et al. Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. Int J Cancer 2012; 130: 1284-1293.
45. Gilad AA, Israely T, Dafni H et al. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumour angiogenesis. Int J Cancer 2005; 117: 202-211.
46. Gross S, Gilead A, Scherz A et al. Monitoring photodynamic therapy of solid tumours online by BOLD-contrast MRI. Nat Med 2003; 9: 1327-1331.
47. Cai K, Shore A, Singh A et al. Blood oxygen level dependent angiography (BOLDangio) and its potential applications in cancer research. NMR Biomed 2012; 25: 1125-1132.
48. Kiessling F, Huppert J, Zhang C et al. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumour compartment. Radiology 2009; 253: 462-469.
49. Frascione D, Diwoky C, Almer G et al. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomedicine 2012; 7: 2349-2359.
50. Mulder WJ, Strijkers GJ, van Tilborg GA et al. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006; 19: 142-164.
51. Mulder WJ, van der Schaft DW, Hautvast PA et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 2007; 21: 378-383.
52. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumour angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 2007; 14: 77-91.
53. Sipkins DA, Cheresh DA, Kazemi MR et al. Detection of tumour angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998; 4: 623-626.
54. Makowski MR, Wiethoff AJ, Blume U et al. Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nat Med 2011; 17: 383-388.
55. Zhang C, Jugold M, Woenne EC et al. Specific targeting of tumour angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67: 1555-1562.
56. Kiessling F, Huppert J, Palmowski M. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 2009; 16: 627-642.
57. Iordanescu I, Becker C, Zetter B et al. Tumour vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 2002; 222: 460-467.
58. Denis F, Bougnoux P, de Poncheville L et al. In vivo quantitation of tumour vascularisation assessed by Doppler sonography in rat mammary tumours. Ultrasound Med Biol 2002; 28: 431-437.
59. Jugold M, Palmowski M, Huppert J et al. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumour xenografts in nude mice. Eur Radiol 2008; 18: 753-758.
60. Krix M, Kiessling F, Essig M et al. Low mechanical index contrast-enhanced ultrasound better reflects high arterial perfusion of liver metastases than arterial phase computed tomography. Invest Radiol 2004; 39: 216-222.
61. Palmowski M, Lederle W, Gaetjens J et al. Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. Eur J Radiol 2010; 75: 149-153.
62. Rix A, Lederle W, Siepmann M et al. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumour response to anti-angiogenic treatment. Eur J Radiol 2012; 81: 2710-2716.
63. Sirsi SR, Flexman ML, Vlachos F et al. Contrast ultrasound imaging for identification of early responder tumour models to anti-angiogenic therapy. Ultrasound Med Biol 2012; 38: 1019-1029.
64. Palmowski M, Huppert J, Hauff P et al. Vessel fractions in tumour xenografts depicted by flow-or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 2008; 68: 7042-7049.
65. Krix M, Kiessling F, Vosseler S et al. Sensitive noninvasive monitoring of tumour perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 2003; 63: 8264-8270.
66. Palmowski M, Morgenstern B, Hauff P et al. Pharmacodynamics of streptavidin-coated cyanoacrylate microbubbles designed for molecular ultrasound imaging. Invest Radiol 2008; 43: 162-169.
67. Kiessling F, Fokong S, Koczera P et al. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med 2012; 53: 345-348.
68. Palmowski M, Huppert J, Ladewig G et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther 2008; 7: 101-109.
69. Palmowski M, Peschke P, Huppert J et al. Molecular ultrasound imaging of early vascular response in prostate tumours irradiated with carbon ions. Neoplasia 2009; 11: 856-863.
70. Pysz MA, Foygel K, Rosenberg J et al. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256: 519-527.
71. Bzyl J, Palmowski M, Rix A et al. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). Eur Radiol 2012; 23: 468-475.
72. Eisenblätter M, Höltke C, Persigehl T et al. Optical techniques for the molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging 2010; 37 (Suppl 1): 127-137.
73. Ale A, Ermolayev V, Herzog E et al. FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography. Nat Methods 2012; 9: 615-620.
74. Kunjachan S, Gremse F, Theek B et al. Non-invasive optical imaging of nanomedicine biodistribution. ACS Nano 2012; 7: 252-262.
75. Zhang Q, Bindokas V, Shen J et al. Time-course imaging of therapeutic functional tumour vascular normalisation by antiangiogenic agents. Mol Cancer Ther 2011; 10: 1173-1184.
76. Lederle W, Arns S, Rix A et al. Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects. EJNMMI Res 2011; 1: 26.
77. Chang SK, Rizvi I, Solban N et al. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res 2008; 14: 4146-4153.
78. Wang H, Chen K, Niu G et al. Site-specifically biotinylated VEGF(121) for nearinfrared fluorescence imaging of tumour angiogenesis. Mol Pharm 2009; 6: 285-294.
79. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB et al. Intraoperative near-infrared fluorescence tumour imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 2011; 52: 1778-1785.
80. Snoeks T, Löwik C, Kaijzel E. In vivo optical approaches to angiogenesis imaging. Angiogenesis 2010; 13: 135-147.
81. Zhang N, Fang Z, Contag PR et al. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004; 103: 617-626.
82. Kishimoto J, Ehama R, Ge Y et al. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol 2000; 157: 103-110.
83. Wang Y, Iyer M, Annala A et al. Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice. Physiol Genomics 2006; 24: 173-180.
84. Wang LV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 2012; 335: 1458-1462.
85. Laufer J, Zhang E, Raivich G et al. Three-dimensional noninvasive imaging of the vasculature in the mouse brain using a high resolution photoacoustic scanner. Appl Opt 2009; 48: D299-306.
86. De la Zerda A, Zavaleta C, Keren S et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008; 3: 557-562.
87. Cai X, Li L, Krumholz A et al. Multi-scale molecular photoacoustic tomography of gene expression. PLoS One 2012; 7: e43999.
88. Cai W, Chen X. Multimodality molecular imaging of tumour angiogenesis. J Nucl Med 2008; 49 (Suppl 2): 113S-28S.
89. Cai W, Chen K, Mohamedali KA et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-2056.
90. Cao F, Li Z, Lee A et al. Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res 2009; 69: 2709-2713.
91. Liu Z, Jia B, Zhao H et al. Specific targeting of human integrin _(v)_ (3) with (111)In-labeled Abegrin™ in nude mouse models. Mol Imaging Biol 2011; 13: 112-120.
92. Jia B, Shi J, Yang Z et al. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Bioconjug Chem 2006; 17: 1069-1076.
93. Yang M, Gao H, Yan Y et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 2011; 38: 1237-1247.
94. Jin ZH, Furukawa T, Claron M et al. Positron emission tomography imaging of tumour angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe (64)Cu-cyclam-RAFT-c(-RGDfK-) (4). Angiogenesis 2012; 15: 569-580.
95. Jati A, Tatli{dotless} S, Morgan JA et al. Imaging features of bone metastases in patients with gastrointestinal stromal tumours. Diagn Interv Radiol 2012; 18: 391-396.
96. Schwarzenberg J, Czernin J, Cloughesy TF et al. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012; 53: 29-36.
97. Metz S, Ganter C, Lorenzen S et al. Phenotyping of tumour biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med 2010; 51: 1691-1698.
98. Bach-Gansmo T, Danielsson R, Saracco A et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006; 47: 1434-1439.
99. Van der Veldt AA, Lubberink M, Bahce I et al. Rapid decrease in delivery of chemotherapy to tumours after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21: 82-91.
100. Fokong S, Theek B, Wu Z et al. Image-guided, targeted and triggered drug delivery to tumours using polymer-based microbubbles. J Control Release 2012; 163: 75-81.